

Results of individual trials (August 2019 update)

Overall survival (OS) and progression-free survival (PFS)

Trials	Treatment (arm 1)	Treatment (arm 2)	OS,HR (95%CI)	PFS,HR (95%CI)
ARCHER 1009, 2014	Dacomitinib	Erlotinib	1.03(0.89-1.19)	0.93(0.80-1.10)
ARQ 197-209, 2011	Erlotinib+Tivantinib	Erlotinib	0.87(0.59-1.27)	0.74(0.51-1.06)
ATTENTION, 2015	Erlotinib+Tivantinib	Erlotinib	0.89(0.67-1.18)	0.72(0.54-0.95)
Bergqvist, 2014	AXL1717	Docetaxel	1.10(0.80-1.50)	1.30(0.83-2.02)
Besse, 2014	Erlotinib+Everolimus	Erlotinib	1.28(0.69-2.37)	0.77(0.51-1.17)
BeTa, 2011	Erlotinib+Bevacizumab	Erlotinib	0.97(0.8-1.18)	0.62(0.52-0.75)
Bhatnagar, 2012	Docetaxel	Gefitinib	-	-
Blumenschein, 2015	Docetaxel	Trametinib	0.97(0.52-1.83)	1.23(0.81-1.87)
BR21, 2005	Erlotinib	Placebo	0.73(0.60-0.87)	0.61(0.51-0.73)
CALGB 30704, 2014	Sunitinib	Pemetrexed	1.40(0.90-2.30)	1.40(0.90-2.20)
CALGB 30704, 2014	Pemetrexed+Sunitinib	Sunitinib	2.00(1.20-3.20)	1.30(0.90-2.10)
CheckMate017, 2015	Nivolumab	Docetaxel	0.62(0.47-0.8)	0.62(0.47-0.81)
CheckMate057, 2015	Nivolumab	Docetaxel	0.75(0.63-0.91)	0.89(0.74-1.06)
Chen, 2011	Tegafur/uracil+Gefitinib	Gefitinib	0.82 (0.48-1.40)	0.65(0.43-0.97)
CTONG0806, 2014	Pemetrexed	Gefitinib	0.72(0.49-1.04)	0.53(0.38-0.75)
Dai, 2013	Gefitinib	Pemetrexed	-	0.77(0.42-1.43)
DATE, 2015	Gefitinib+Nimotuzumab	Gefitinib	0.86(0.57-1.30)	1.03(0.71-1.41)
DELTA, 2014	Erlotinib	Docetaxel	0.91(0.68-1.22)	1.22(0.97-1.55)
Dittrich, 2014	Pemetrexed+Erlotinib	Pemetrexed	0.68(0.47-0.98)	0.63(0.44-0.90)
E1512, 2015	Cabozantinib	Erlotinib	0.68(0.33-1.03)	0.39(0.17-0.61)
E1512, 2015	Erlotinib+Cabozantinib	Erlotinib	0.51(0.22-0.80)	0.37(0.15-0.58)
Esteban, 2003	Paclitaxel	Docetaxel	1.84 (1.12-3.02)	-
Gerber, 2014	Erlotinib+Tivantinib	Chemotherapy	1.2(0.76-1.88)	1.19(0.71-1.97)
GFPC 05-06, 2011	Pemetrexed	Docetaxel	0.85(0.61-1.20)	0.93(0.67-1.29)
Groen, 2013	Erlotinib+Sunitinib	Erlotinib	1.07(0.71-1.61)	0.90(0.46-1.76)
Hainsworth, 2010	Selumetinib	Pemetrexed	-	1.08(0.62-1.86)
Han, 2011	Pemetrexed	Docetaxel	-	-
HANSHIN, 2015	Docetaxel+Bevacizumab	S1+Bevacizumab	1.25(0.73-2.14)	0.84(0.53-1.32)
Herbst, 2007	Chemotherapy+Bevacizumab	Chemotherapy	0.71(0.41-1.21)	0.66(0.38-1.16)
Herbst, 2007	Erlotinib+Bevacizumab	Chemotherapy	0.78(0.46-1.31)	0.72(0.42-1.23)
Heymach, 2007	Docetaxel+Vandetanib	Docetaxel	0.91(0.55-1.52)	0.64(0.38-1.05)
HORG, 2013	Pemetrexed	Erlotinib	0.99(0.78-1.29)	-

Hosomi, 2015	Docetaxel+Ramucirumab	Docetaxel	0.86 (0.56-1.32)	0.83(0.59-1.16)
ICOGN, 2013	Icotinib	Gefitinib	1.02(0.82-1.27)	0.84(0.67-1.05)
INTEREST, 2008	Gefitinib	Docetaxel	1.02(0.91-1.14)	1.04(0.93-1.16)
ISEL, 2005	Gefitinib	Placebo	0.89(0.77-1.02)	-
ISTANA, 2010	Gefitinib	Docetaxel	0.87(0.61-1.24)	0.73(0.50-1.06)
Janne, 2013	Docetaxel+Selumetinib	Docetaxel	0.81(0.48-1.36)	0.58(0.36-0.94)
JMEI, 2004	Pemetrexed	Docetaxel	0.99(0.82-1.20)	0.97(0.82-1.16)
Jones, 2008	Topotecan	Docetaxel	0.79 (0.50-1.25)	-
Juan, 2014	Docetaxel+Erlotinib	Erlotinib	0.70(0.41-1.19)	0.65(0.39-1.06)
Kapoor, 2015	Gefitinib	Docetaxel	0.89(0.49-1.29)	1.12(0.77-1.45)
Katakami, 2014	Amrubicin	Docetaxel	1.02(0.72-1.43)	0.96(0.69-1.34)
KCSG-LU08-01, 2012	Gefitinib	Pemetrexed	0.80(0.50-1.30)	0.54(0.37-0.79)
Kelly, 2012	Pralatrexate	Erlotinib	0.83(0.61-1.13)	0.91(0.63-1.32)
KEYNOTE-010,2015	Pembrolizumab	Docetaxel	0.71(0.58-0.88)	0.88(0.73-1.04)
Kim A, 2012	Pemetrexed+Cetuximab	Pemetrexed	1.01(0.86-1.20)	1.03(0.87-1.21)
Kim B, 2012	Docetaxel+Cetuximab	Docetaxel	1.13(0.90-1.41)	0.91(0.73-1.13)
Kim, 2015	Pemetrexed	Gefitinib	0.98(0.64-1.50)	0.96(0.64-1.44)
Krzakowski, 2010	Vinflunine	Docetaxel	0.97(0.81-1.18)	1.00(0.84-1.12)
Kuo, 2013	Docetaxel	Gefitinib	-	-
Lee, 2013	Pemetrexed+Erlotinib	Erlotinib	1.08(0.69-1.67)	0.57(0.40-0.81)
Lee, 2013	Pemetrexed+Erlotinib	Pemetrexed	0.75(0.49-1.13)	0.58(0.39-0.85)
Lee, 2013	Erlotinib	Pemetrexed	0.69(0.45-1.06)	1.01(0.71-1.43)
Levy, 2014	Docetaxel+PX-866	Docetaxel	1.49 (0.90-2.48)	1.08 (0.71-1.63)
Li, 2010	Gefitinib	Docetaxel	0.97(0.63-1.49)	-
Li, 2012	Pemetrexed	Docetaxel	-	-
Li, 2013	Pemetrexed+Erlotinib	Pemetrexed	0.71(0.42-1.11)	0.63(0.40-1.00)
Li, 2014	Erlotinib	Pemetrexed	1.01(0.66-1.54)	0.92(0.62-1.37)
Liu, 2015	Nab-Paclitaxel	Pemetrexed	1.23(0.78-1.59)	1.12(0.69-1.31)
LUME-COLUMBUS,2016	Docetaxel+Nintedanib	Docetaxel	-	-
LUME-LUNG 1, 2014	Docetaxel+Nintedanib	Docetaxel	0.94(0.83-1.05)	0.85(0.75-0.96)
LUME-LUNG 2, 2013	Pemetrexed+Nintedanib	Pemetrexed	1.01(0.85-1.21)	0.84(0.70-1.00)
Lux-Lung 8, 2015	Afatinib	Erlotinib	0.81(0.69-0.95)	0.82(0.68-0.99)
Maitland, 2014	Pemetrexed+Cetuximab	Cetuximab	0.63(0.32-1.26)	0.59(0.32-1.10)
Marangolo, 2000	Docetaxel	Vinorelbine	-	-
MARQUEE, 2013	Erlotinib+Tivantinib	Erlotinib	0.98(0.84-1.14)	0.74(0.64-0.85)
MARVEL, 2013	Erlotinib	Pemetrexed	-	-
METLung, 2014	Erlotinib+Onartuzumab	Erlotinib	1.27(0.98-1.65)	1,08(0.85-1.08)
Moran, 2014	Erlotinib+Dalotuzumab	Erlotinib	1.44(0.78-2.64)	0.86(0.47-1.57)

Natale, 2009	Vandetanib	Gefitinib	1.19(0.84-1.68)	0.69(0.50-0.96)
NCCTG N0626, 2011	Pemetrexed+Sorafenib	Pemetrexed	-	-
NCIC CTG BR.26, 2014	Dacomitinib	Placebo	1.00(0.83-1.21)	0.66(0.55-0.79)
NVALT-10, 2013	Erlotinib+Chemotherapy	Erlotinib	0.67(0.49-0.91)	0.76(0.58-1.02)
OAK,2016	Atezolizumab	Docetaxel	0.79 (0.69-0.91)	0.96 (0.85-1.08)
Paz-Ares, 2008	Docetaxel	Paclitaxel	1.09(0.94-1.27)	-
POPLAR, 2016	Atezolizumab	Docetaxel	0.69(0.52-0.92)	0.94(0.72-1.23)
PROSE, 2014	Chemotherapy	Erlotinib	1.14(0.88-1.49)	1.27(0.99-1.62)
Ramalingam, 2011	Erlotinib+R1507	Erlotinib	0.72(0.50-1.04)	0.93(0.64-1.36)
Ramalingam, 2012	Dacomitinib	Erlotinib	0.82(0.59-1.15)	0.66(0.47-0.91)
Ramlau, 2006	Topotecan	Docetaxel	1.16(1.00-1.35)	-
Ramlau, 2012	Docetaxel+Aflibercept	Docetaxel	1.01(0.87-1.17)	0.82(0.72-0.94)
REVEL, 2014	Docetaxel+Ramucirumab	Docetaxel	0.86(0.75-0.98)	0.76(0.68-0.86)
Sbar, 2010	Erlotinib	BMS-690514	-	-
Scagliotti, 2012	Erlotinib+Sunitinib	Erlotinib	0.94(0.82-1.08)	0.81(0.70-0.94)
Scagliotti, 2014	Erlotinib+Figitumumab	Erlotinib	1.09(0.91-1.31)	1.08(0.90-1.29)
Schiller, 2010	Pemetrexed+Matuzumab	Pemetrexed	1.66(0.97-2.86)	1.46(0.90-2.38)
SELECT 1,2017	Docetaxel+Selumetinib	Docetaxel	1.05 (0.85-1.30)	0.93 (0.77-1.12)
SIGN, 2006	Gefitinib	Docetaxel	0.97(0.61-1.52)	0.94(0.64-1.39)
Spigel, 2011	Erlotinib+Sorafenib	Erlotinib	0.89(0.59-1.34)	0.86(0.60-1.22)
Spigel, 2012	Erlotinib+Pazopanib	Erlotinib	1.10(0.77-1.55)	0.59(0.43-0.83)
Spigel, 2013	Erlotinib+Onartuzumab	Erlotinib	0.80(0.50-1.28)	1.09(0.73-1.62)
Sun, 2013	Pemetrexed	Docetaxel	1.02(0.74-1.40)	1.05(0.75-1.46)
TAILOR, 2013	Docetaxel	Erlotinib	0.78(0.51-1.05)	0.72(0.55-0.94)
TALISMAN, 2015	Docetaxel+Erlotinib	Erlotinib	0.87 (0.51-1.48)	0.96 (0.58-1.58)
TAX 317, 2000	Docetaxel	Placebo	0.56(0.35-0.88)	-
TITAN, 2012	Erlotinib	Chemotherapy	0.96(0.78-1.19)	1.19(0.97-1.46)
TORI L-03, 2013	Erlotinib+Fulvestrant	Erlotinib	0.96(0.60-1.55)	0.85(0.55-1.33)
ULTIMATE, 2016	Paclitaxel+Bevacizumab	Docetaxel	1.25 (0.88-1.78)	0.62 (0.44-0.87)
V15-32, 2008	Gefitinib	Docetaxel	1.12(0.89-1.40)	0.90(0.72-1.12)
Wen, 2016	Docetaxel+Tamoxifen	Docetaxel	0.72(0.48-1.06)	0.67(0.45-0.96)
Witta, 2012	Entinostat+Erlotinib	Erlotinib	0.85(0.59-1.23)	0.99(0.68-1.44)
WJOG 5108L, 2016	Gefitinib	Erlotinib	1.03(0.83-1.29)	1.07(0.89-1.28)
ZEAL, 2011	Pemetrexed+Vandetanib	Pemetrexed	0.86(0.68-1.09)	0.86(0.71-1.04)
ZEST, 2011	Vandetanib	Erlotinib	1.01(0.89-1.15)	0.98(0.87-1.10)
Zhang, 2015	Nab-Paclitaxel+Erlotinib	Erlotinib	0.68(0.25-0.81)	0.24(0.14-0.74)
ZODIAC, 2010	Docetaxel+Vandetanib	Docetaxel	0.91(0.79-1.04)	0.79(0.71-0.88)

<i>East Asia S-1 Trial in Lung Cancer, 2017</i>	<i>S-1</i>	<i>Docetaxel</i>	<i>0,95(0.83-1.07)</i>	<i>1.03(0.91-1.17)</i>
<i>Fandi, 2018</i>	<i>CC-486 + Pembrolizumab</i>	<i>placebo + Pembrolizumab</i>	<i>1,38(0.83-2.28)</i>	<i>1.37(0.93-2.00)</i>
<i>SELECT-2, 2017</i>	<i>Selumetinib + docetaxel 60</i>	<i>Placebo + docetaxel 75</i>	<i>1,43(0.97-2.13)</i>	<i>1.12(0.8-1.61)</i>
<i>SELECT-2, 2017</i>	<i>Selumetinib + docetaxel 75</i>	<i>Placebo + docetaxel 75</i>	<i>1,18(0.80-1.78)</i>	<i>0.92(0.65-1.31)</i>
<i>Wu, 2017</i>	<i>Nab-paclitaxel</i>	<i>Placebo</i>	<i>0.71(0.30-0.85)</i>	<i>0.62(0.33-0.81)</i>
<i>Yu, 2018</i>	<i>Apatinib+docetaxel or pemetrexed</i>	<i>Docetaxel or pemetrexed</i>	<i>NA</i>	<i>NA</i>
<i>JAVELIN, 2018</i>	<i>Avelumab</i>	<i>Docetaxel</i>	<i>0.9 (0.75-1.08)</i>	<i>1.16(0.97-1.4)</i>
CHECKMATE 078	Nivolumab	Docetaxel	0.68(0.52-0.9)	0.77(0.62-0.95)
Sequist 2019	Seribantumab +erlotinib	erlotinib	1.32(0.8-2.2)	0.81(0.55-1.2)
NCT03023423 2019	Daratumumab + Atezolizumab	Azeulizumab		
Lung-MAP Sub-Study S14001	Ipilimumab + Nivolumab	Nivolumab	0.97(0.71-1.31)	0.84(0.64-1.09)

In *blue italic bold* are the results of the 2018 update

In *dark red italic bold* are the results of the 2019 update

Objective response rate (ORR)

Trials	Treatment (arm 1)	ORR	Treatment (arm 2)	ORR	Treatment (arm 3)	ORR
ARCHER 1009, 2014	Dacomitinib	12%	Erlotinib	8%		
ARQ 197-209, 2011	Erlotinib+Tivantinib	8%	Erlotinib	6%		
ATTENTION, 2015	Erlotinib+Tivantinib	8%	Erlotinib	7%		
Bergqvist, 2014	AXL1717	0%	Docetaxel	12%		
Besse, 2014	Erlotinib+Everolimus	12%	Erlotinib	10%		
BeTa, 2011	Erlotinib+Bevacizumab	12%	Erlotinib	6%		
Bhatnagar, 2012	Docetaxel	27%	Gefitinib	33%		
Blumenschein, 2015	Docetaxel	11%	Trametinib	11%		
BR21, 2005	Erlotinib	8%	Placebo	1%		
CALGB 30704, 2014	Pemetrexed+Sunitinib	22%	Sunitinib	17%	Pemetrexed	14%
CheckMate017, 2015	Nivolumab	20%	Docetaxel	9%		
CheckMate057, 2015	Nivolumab	19%	Docetaxel	12%		
Chen, 2011	Tegafur/uracil+Gefitinib	37%	Gefitinib	34%		
CTONG0806, 2014	Pemetrexed	14%	Gefitinib	12%		
Dai, 2013	Gefitinib	17%	Pemetrexed	13%		
DATE, 2015	Gefitinib+Nimotuzumab	17%	Gefitinib	22%		
DELTA, 2014	Erlotinib	17%	Docetaxel	17%		
Dittrich, 2014	Pemetrexed+Erlotinib	16%	Pemetrexed	11%		
E1512, 2015	Cabozantinib	10%	Erlotinib+Cabozantinib	5%	Erlotinib	2%
Esteban, 2003	Paclitaxel	14%	Docetaxel	3%		
Gerber, 2014	Erlotinib+Tivantinib	0%	Chemotherapy	9%		
GFPC 05-06, 2011	Pemetrexed	12%	Docetaxel	11%		
Groen, 2013	Erlotinib+Sunitinib	5%	Erlotinib	3%		
Hainsworth, 2010	Selumetinib	5%	Pemetrexed	5%		
Han, 2011	Pemetrexed	14%	Docetaxel	10%		

HANSHIN, 2015	Docetaxel+Bevacizumab	20%	S1+Bevacizumab	2%		
Herbst, 2007	Erlotinib+Bevacizumab	18%	Chemotherapy+Bev acizumab	13%	Chemotherapy	12%
Heymach, 2007	Docetaxel+Vandetanib	26%	Docetaxel	12%		
HORG, 2013	Pemetrexed	11%	Erlotinib	8%		
Hosomi, 2015	Docetaxel+Ramucirumab	28%	Docetaxel	19%		
ICOGN, 2013	Icotinib	28%	Gefitinib	27%		
INTEREST, 2008	Gefitinib	8%	Docetaxel	7%		
ISEL, 2005	Gefitinib	7%	Placebo	1%		
ISTANA, 2010	Gefitinib	28%	Docetaxel	8%		
Janne, 2013	Docetaxel+Selumetinib	36%	Docetaxel	0%		
JMEI, 2004	Pemetrexed	8%	Docetaxel	8%		
Jones, 2008	Topotecan	8%	Docetaxel	7%		
Juan, 2014	Docetaxel+Erlotinib	3%	Erlotinib	8%		
Kapoor, 2015	Gefitinib	-	Docetaxel	-		
Katakami, 2014	Amrubicin	14%	Docetaxel	19%		
KCSG-LU08-01, 2012	Gefitinib	44%	Pemetrexed	27%		
Kelly, 2012	Pralatrexate	2%	Erlotinib	7%		
KEYNOTE-010,2015	Pembrolizumab	18%	Docetaxel	9%		
Kim A, 2012	Pemetrexed+Cetuximab	7%	Pemetrexed	4%		
Kim B, 2012	Docetaxel+Cetuximab	8%	Docetaxel	7%		
Kim, 2015	Pemetrexed	13%	Gefitinib	8%		
Krzakowski, 2010	Vinflunine	4%	Docetaxel	5%		
Kuo, 2013	Docetaxel	-	Gefitinib	-		
Lee, 2013	Pemetrexed+Erlotinib	44%	Erlotinib	29%	Pemetrexed	10%
Levy, 2014	Docetaxel+PX-866	6%	Docetaxel	0%		
Li, 2010	Gefitinib	22%	Docetaxel	19%		
Li, 2012	Pemetrexed	8%	Docetaxel	4%		

Li, 2013	Pemetrexed+Erlotinib	27%	Pemetrexed	11%
Li, 2014	Erlotinib	20%	Pemetrexed	8%
Liu, 2015	Nab-Paclitaxel	15%	Pemetrexed	11%
LUME-COLUMBUS, 2016	Docetaxel+Nintedanib	-	Docetaxel	-
LUME-LUNG 1, 2014	Docetaxel+Nintedanib	4%	Docetaxel	3%
LUME-LUNG 2, 2013	Pemetrexed+Nintedanib	9%	Pemetrexed	8%
Lux-Lung 8, 2015	Afatinib	4%	Erlotinib	3%
Maitland, 2014	Pemetrexed+Cetuximab	13%	Cetuximab	0%
Marangolo, 2000	Docetaxel	7%	Vinorelbine	0%
MARQUEE, 2013	Erlotinib+Tivantinib	10%	Erlotinib	7%
MARVEL, 2013	Erlotinib	-	Pemetrexed	-
METLung, 2014	Erlotinib+Onartuzumab	6%	Erlotinib	9%
Moran, 2014	Erlotinib+Dalotuzumab	3%	Erlotinib	8%
Natale, 2009	Vandetanib	8%	Gefitinib	1%
NCCTG N0626, 2011	Pemetrexed+Sorafenib	13%	Pemetrexed	10%
NCIC CTG BR.26, 2014	Dacomitinib	7%	Placebo	1%
NVALT-10, 2013	Erlotinib+Chemotherapy	13%	Erlotinib	7%
OAK, 2016	Atezolizumab	14%	Docetaxel	12%
Paz-Ares, 2008	Docetaxel	12%	Paclitaxel	8%
POPLAR, 2016	Atezolizumab	15%	Docetaxel	15%
PROSE, 2014	Chemotherapy	9%	Erlotinib	7%
Ramalingam, 2011	Erlotinib+R1507	7%	Erlotinib	9%
Ramalingam, 2012	Dacomitinib	17%	Erlotinib	5%
Ramlau, 2006	Topotecan	5%	Docetaxel	5%
Ramlau, 2012	Docetaxel+Aflibercept	21%	Docetaxel	8%

REVEL, 2014	Docetaxel+Ramucirumab	23%	Docetaxel	14%
Sbar, 2010	Erlotinib	-	BMS-690514	-
Scagliotti, 2012	Erlotinib+Sunitinib	11%	Erlotinib	7%
Scagliotti, 2014	Erlotinib+Figitumumab	5%	Erlotinib	4%
Schiller, 2010	Pemetrexed+Matuzumab	2%	Pemetrexed	4%
SELECT 1,2017	Docetaxel+Selumetinib	20%	Docetaxel	14%
SIGN, 2006	Gefitinib	13%	Docetaxel	14%
Spigel, 2011	Erlotinib+Sorafenib	8%	Erlotinib	11%
Spigel, 2012	Erlotinib+Pazopanib	9%	Erlotinib	4%
Spigel, 2013	Erlotinib+Onartuzumab	6%	Erlotinib	4%
Sun, 2013	Pemetrexed	9%	Docetaxel	4%
TAILOR, 2013	Docetaxel	14%	Erlotinib	3%
TALISMAN, 2015	Docetaxel+Erlotinib	8%	Erlotinib	3%
TAX 317, 2000	Docetaxel	5%	Placebo	0%
TITAN, 2012	Erlotinib	8%	Chemotherapy	6%
TORI L-03, 2013	Erlotinib+Fulvestrant	24%	Erlotinib	14%
ULTIMATE, 2016	Paclitaxel+Bevacizumab	23%	Docetaxel	5%
V15-32, 2008	Gefitinib	18%	Docetaxel	10%
Wen, 2016	Docetaxel+Tamoxifen	37%	Docetaxel	15%
Witta, 2012	Entinostat+Erlotinib	3%	Erlotinib	9%
WJOG 5108L, 2016	Gefitinib	40%	Erlotinib	36%
ZEAL, 2011	Pemetrexed+Vandetanib	19%	Pemetrexed	8%
ZEST, 2011	Vandetanib	12%	Erlotinib	12%
Zhang, 2015	Nab-Paclitaxel+Erlotinib	33%	Erlotinib	19%
ZODIAC, 2010	Docetaxel+Vandetanib	17%	Docetaxel	10%

<i>East Asia S-1 Trial in Lung Cancer, 2017</i>	<i>S-1</i>	<i>7%</i>	<i>Docetaxel</i>	<i>9%</i>		
<i>Fandi, 2018</i>	<i>CC-486 + Pembrolizumab</i>	<i>20%</i>	<i>placebo + Pembrolizumab</i>	<i>14%</i>		
<i>SELECT-2, 2017</i>	<i>Selumetinib + docetaxel 60</i>	<i>18%</i>	<i>Selumetinib + docetaxel 75</i>	<i>33%</i>	<i>Placebo + docetaxel 75</i>	<i>14%</i>
<i>Wu, 2017</i>	<i>Nab-paclitaxel</i>	<i>20%</i>	<i>Placebo</i>	<i>4%</i>		
<i>Yu, 2018</i>	<i>Apatinib+docetaxel/or pemetrexed</i>		<i>Docetaxel/ or pemetrexed</i>			
<i>JAVELIN, 2018</i>	<i>Avelumab</i>	<i>15%</i>	<i>Docetaxel</i>	<i>11%</i>		
CHECKMATE 078	Nivolumab	17%	Docetaxel	4%		
Sequist 2019	Seribantumab +erlotinib	6%	Erlotinib	4%		
NCT03023423 2019	Daratumumab + Atezolizumab	13%	Atezolizumab	4%		
Lung-MAP Sub-Study S14001	Ipilimumab + Nivolumab	18%	Nivolumab	17%		

Serious adverse events (SAE)

Trials	Treatment (arm 1)	SAE (%)	Treatment (arm 2)	SAE (%)	Treatment (arm 3)	SAE (%)
ARCHER 1009, 2014	Dacomitinib	41%	Erlotinib	39%		
Besse, 2014	Erlotinib+Everolimus	41%	Erlotinib	18%		
BeTa, 2011	Erlotinib+Bevacizumab	42%	Erlotinib	36%		
Bhatnagar, 2012	Docetaxel	13%	Gefitinib	0%		
Blumenschein, 2015	Trametinib	37%	Docetaxel	21%		
CALGB 30704, 2014	Pemetrexed+Sunitinib	51%	Sunitinib	40%	Pemetrexed	31%
CheckMate017, 2015	Nivolumab	47%	Docetaxel	54%		
CheckMate057, 2015	Nivolumab	47%	Docetaxel	41%		
Dittrich, 2014	Pemetrexed+Erlotinib	70%	Pemetrexed	52%		
E1512, 2015	Erlotinib+Cabozantinib	72%	Cabozantinib	70%	Erlotinib	33%
Gerber, 2014	Erlotinib+Tivantinib	4%	Chemotherapy	11%		
Groen, 2013	Erlotinib+Sunitinib	45%	Erlotinib	44%		
Hainsworth, 2010	Selumetinib	3%	Pemetrexed	7%		
Herbst, 2007	Chemotherapy+Bevacizumab	41%	Chemotherapy	55%	Erlotinib+Bevacizumab	33%
Hosomi, 2015	Docetaxel+Ramucirumab	32%	Docetaxel	32%		
ICOGN, 2013	Icotinib	7%	Gefitinib	8%		
INTEREST, 2008	Gefitinib	22%	Docetaxel	29%		
ISTANA, 2010	Docetaxel	25%	Gefitinib	16%		
Janne, 2013	Docetaxel+Selumetinib	84%	Docetaxel	67%		
Katakami, 2014	Amrubicin	15%	Docetaxel	22%		
KCSG-LU08-01, 2012	Pemetrexed	15%	Gefitinib	19%		
Kelly, 2012	Pralatrexate	32%	Erlotinib	32%		
KEYNOTE-010,2015	Pembrolizumab	34%	Docetaxel	35%		
Kim A, 2012	Pemetrexed+Cetuximab	41%	Pemetrexed	30%		

Kim B, 2012	Docetaxel+Cetuximab	53%	Docetaxel	40%		
Kuo, 2013	Docetaxel	17%	Gefitinib	25%		
Lee, 2013	Pemetrexed+Erlotinib	33%	Pemetrexed	29%	Erlotinib	22%
Li, 2014	Erlotinib	7%	Pemetrexed	5%		
LUME-COLUMBUS, 2016	Docetaxel+Nintedanib	50%	Docetaxel	50%		
LUME-LUNG 1, 2014	Docetaxel+Nintedanib	34%	Docetaxel	31%		
LUME-LUNG 2, 2013	Pemetrexed+Nintedanib	30%	Pemetrexed	33%		
Lux-Lung 8, 2015	Afatinib	39%	Erlotinib	38%		
Maitland, 2014	Pemetrexed+Cetuximab	30%	Cetuximab	55%		
MARQUEE, 2013	Erlotinib+Tivantinib	42%	Erlotinib	37%		
MARVEL, 2013	Erlotinib	0%	Pemetrexed	0%		
Moran, 2014	Erlotinib+Dalotuzumab	51%	Erlotinib	58%		
NCCTG N0626, 2011	Pemetrexed+Sorafenib	28%	Pemetrexed	14%		
NCIC CTG BR.26, 2014	Dacomitinib	40%	Placebo	36%		
OAK, 2016	Atezolizumab	32%	Docetaxel	31%		
POPLAR, 2016	Atezolizumab	35%	Docetaxel	34%		
PROSE, 2014	Chemotherapy	2%	Erlotinib	3%		
Ramalingam, 2011	Erlotinib+R1507	25%	Erlotinib	14%		
Ramalingam, 2012	Dacomitinib	37%	Erlotinib	32%		
Ramlau, 2012	Docetaxel+Aflibercept	48%	Docetaxel	35%		
REVEL, 2014	Docetaxel+Ramucirumab	45%	Docetaxel	45%		
Scagliotti, 2012	Erlotinib+Sunitinib	44%	Erlotinib	38%		
Scagliotti, 2014	Erlotinib+Figitumumab	71%	Erlotinib	53%		
Schiller, 2010	Pemetrexed+Matuzumab	23%	Pemetrexed	18%		
SELECT 1, 2017	Docetaxel+Selumetinib	49%	Docetaxel	32%		
Spigel, 2012	Erlotinib+Pazopanib	35%	Erlotinib	28%		
Spigel, 2013	Erlotinib+Onartuzumab	42%	Erlotinib	33%		
Sun, 2013	Docetaxel	8%	Pemetrexed	5%		
TAILOR, 2013	Docetaxel	4%	Erlotinib	2%		

TALISMAN, 2015	Docetaxel+Erlotinib	27%	Erlotinib	42%		
TITAN, 2012	Chemotherapy	15%	Erlotinib	10%		
V15-32, 2008	Gefitinib	17%	Docetaxel	14%		
Witta, 2012	Entinostat+Erlotinib	49%	Erlotinib	46%		
ZEAL, 2011	Pemetrexed+Vandetanib	32%	Pemetrexed	34%		
ZEST, 2011	Vandetanib	22%	Erlotinib	18%		
ZODIAC, 2010	Docetaxel+Vandetanib	38%	Docetaxel	34%		
Fandi, 2018	CC-486 + Pembrolizumab	61%	placebo + Pembrolizumab	55%		
SELECT-2, 2017	Selumetinib + docetaxel 60	48%	Selumetinib + docetaxel 75	45%	Placebo + docetaxel 75	37%
Wu, 2017	Nab-paclitaxel	35%	Placebo	9%		
JAVELIN, 2018	Avelumab	9%	Docetaxel	21%		
CHECKMATE 078	Nivolumab	39%	Docetaxel	30%		
Sequist 2019	Seribantumab +erlotinib	47%	Erlotinib	41%		
NCT03023423 2019	Daratumumab + Atezolizumab	48%	Atezolizumab	34%		